---
schema_version: "secwatch.filing_event.v1"
accession: "0001079973-26-001006"
form_type: "8-K"
ticker: "TOI"
cik: "0001799191"
company_name: "Oncology Institute, Inc."
filed_at: "2026-08-06T20:32:33+00:00"
generated_at: "2026-08-06T20:35:13.964421+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Starling Oncology Q2 revenue up 34.6% to $161.3M; raises FY2026 guidance

## Summary
- Revenue $161.3M (+34.6% YoY); gross profit $27.2M (+55.2%).
- Net loss narrowed to $9.8M from $17.0M; EPS $(0.08) vs $(0.15).
- Adjusted EBITDA turned positive at $229K vs $(4.1M) loss in prior year.
- Specialty Pharmacy revenue up 58% YoY; added ~230,000 capitated lives in California.
- Raised full-year 2026 revenue and gross profit guidance.

## SEC filing metadata
- accession: 0001079973-26-001006
- form_type: 8-K
- ticker: TOI
- cik: 0001799191
- company_name: Oncology Institute, Inc.
- filed_at: 2026-08-06T20:32:33+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799191/000107997326001006/0001079973-26-001006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799191/000107997326001006/stln_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001079973-26-001006
- JSON: https://secwatch.observer/filing/0001079973-26-001006.json
- Plain text: https://secwatch.observer/filing/0001079973-26-001006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.